Dr. Raymond W. Lam

 

 

 

Raymond W. Lam, MD, FRCPC

email: r.lam@ubc.ca
Twitter: @DrRaymondLam
Abstracts on PubMed
Google Scholar citation index
ORCid citations

 

 

Dr. Raymond W. Lam is Professor and BC Leadership Chair in Depression Research in the Faculty of Medicine, University of British Columbia (UBC). In the UBC Department of Psychiatry, he is the Associate Head for Research and International Affairs, and the Associate Program Director for the Resident Research Track. Dr. Lam is also Director of the Mood Disorders Centre Research, Education, Awareness and Care Hub (MDCreach) at the Djavad Mowafaghian Centre for Brain Health in Vancouver. His research examines clinical and neurobiological factors in seasonal, treatment-resistant and workplace depression, clinical trials and guidelines, digital health technologies, and global mental health. Dr. Lam is also a lead investigator for the Canadian Biomarker Integration Network in Depression (CAN-BIND) and Executive Director of the Asia-Pacific Economic Cooperation (APEC) Digital Hub for Mental Health, hosted at UBC. His research is supported by many agencies and sponsors including the Canadian Institutes of Health Research.

Dr. Lam has published over 470 scientific articles and book chapters (including over 350 peer-reviewed papers), and edited or authored 11 books on depression; Google Scholar lists over 17,000 citations to his published work, with an h-index=73. He sits on the editorial boards of 10 international journals, including CNS Drugs and Chronobiology International. Dr. Lam is a champion for evidence-based medicine and is an editorial advisor for the international Cochrane Collaboration.

Dr. Lam has received many awards for his research and teaching, including the J.M. Cleghorn Award for Clinical Research (Canadian Psychiatric Association, 2015), a Distinguished Achievement Award for Overall Excellence (UBC Faculty of Medicine, 2014), R.O. Jones Memorial Award (Canadian Psychiatric Association, 2007), Silver Anniversary Leadership Award (UBC Medical Alumni, 2006), and the inaugural Douglas Utting Prize and Medal for Depression Research (SMBD-JGH/McGill University, 2001). He is an elected Distinguished Fellow of both the Canadian Psychiatric Association and the American Psychiatric Association, a Foundation Fellow of the International Society for Affective Disorders, and the Past Executive Chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT).

 

Representative Publications

Alonso-Prieto E, Rubino C, Lucey M, Evans VC, Tam EM, Woo C, Iverson GI, Chakrabarty T, Yatham LN, Lam RW. Self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine: Relationships to work functioning. Psychiatry Research 272:144-148, 2019.

Ng C, Goodenow MM, Greenshaw AJ, Upshall P, Lam RW. Inclusion of mental health in global economic development. BJPsych International, published online 21 March 2018.

Lam RW, Lamy F-X, Danchenko N,et al. Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. Neuropsychiatric Disease and Treatment 14:2861-2877, 2018.

Levitan RD, Levitt AJ, Michalak EE, Cheung A, Morehouse R, Ramasubbu R, Yatham LN, Tam EM, Lam RW. Appetitive symptoms differentially predict treatment response to medication, light and placebo in non-seasonal major depression. Journal of Clinical Psychiatry 79:17m11856, 2018.

Sarfati D, Evans VC, Iverson GI, Woo C, Yatham LN, Lam RW. The impact of fatigue and energy on work impairment in patients with major depressive disorder treated with desvenlafaxine. International Clinical Psychopharmacology 32:343-349, 2017.

Lam RW, McIntosh D, Wang JL, et al. CANMAT 2016 clinical guidelines for the management of adults with major depressive disorder. Section 1. Disease burden and principles of care. Canadian Journal of Psychiatry 61: 510-523, 2016.

Kennedy SH (co-1st author), Lam RW (co-1st author), McIntyre RS,et al. CANMAT 2016 clinical guidelines for the management of adults with major depressive disorder. Section 3. Pharmacological treatments. Canadian Journal of Psychiatry, 61:540-560, 2016.

Evans VC, Alamian G, McLeod J, Woo C, Yatham LN, Lam RW. Effects of newer antidepressants on occupational impairment in major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. CNS Drugs 30:405-417, 2016.

Lam RW, Levitt AJ, Levitan RD, Michalak EE, Cheung A, Morehouse R, Ramasubbu R, Yatham LN, Tam EM. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial. JAMA Psychiatry 73:56-63, 2016.

Lam RW, Milev R, Rotzinger S, et al. Discovering biomarkers for antidepressant response: Protocol from the Canadian Biomarker Integration Network in Depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 16:105, 2016.

Lam RW, Iverson GI, Evans VC, Yatham LN, Stewart K, Tam EM, Axler A, Woo C. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. Journal of Affective Disorders 203:55-61, 2016.

McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 45:693-704, 2015.

Song C, Luchtman D, Kang Z, Tam EM, Yatham LN, Su KP, Lam RW. Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. Journal of Affective Disorders 185:90-96, 2015.

Evans VC, Iverson GL, Yatham LN, Lam RW. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: A systematic review. Journal of Clinical Psychiatry 75:1359-1370, 2014.

Lam RW, Parikh SV, Ramasubbu R, Michalak EE, Tam EM, Axler A, Yatham LN, Kennedy SH, Manjunath CV. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder.  British Journal of Psychiatry 203:358-365, 2013.

 

Potential Conflict of Interest Disclosures (2017-2019)

The following are the sources of all income from commercial, not-for-profit, and government organizations (outside of academic salary from the University of British Columbia and clinical income from the BC Ministry of Health).

Ad Hoc Speaker Honoraria: Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Hansoh, Lundbeck, Lundbeck Institute, Pfizer.

Ad Hoc Consulting/Advisory Boards: Akili, Allergan, Asia-Pacific Economic Cooperation, Canadian Depression Research and Intervention Network, Canadian Network for Mood and Anxiety Treatments, CME Institute, Janssen, Lundbeck, Medscape, Mind.Me, Otsuka, Pfizer.

Research Funds (administered through UBC): BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Healthy Minds Canada, Janssen, Lundbeck, MITACS, Movember Foundation, Ontario Brain Institute, Pfizer, St. Jude Medical, University Health Network Foundation, VGH-UBCH Foundation.

Patents/Copyrights: Lam Employment Absence and Productivity Scale (LEAPS).

Book Royalties: Cambridge University Press, Informa Press, Oxford University Press.

Stock/Stock Options: None.

Gifts/Travel (unrelated to speaker expenses): None.

Speaker Boards: None.